With a growing demand for medical cannabis in Poland, Can4Med has signed a supply agreement for medical cannabis products and raw materials in the country.
Currently, over 90 per cent of Polish pharmacies can fill medical cannabis prescriptions. Prescriptions can be given to patients for indications such as pain management, epilepsy, multiple sclerosis and the side effects of chemotherapy.
Can4Med, which specialises in medical products containing THC and cannabinoids, has now obtained authorization to supply the country with cannabis pharmaceuticals.
Read more: Panaxia and Neuraxpharm to bring medical cannabis products to Poland
Under the agreement, it will supply wholesale products, with up to 100kg a month of high THC oil and flower at competitive rates. It is currently in the process of registering the products in Poland.
Founder of Can4Med, Maximilian Weinberg, commented: ”Demand for medical cannabis products is rapidly growing in Poland. While supply constraints and a lack of authorized products has stifled growth in the Polish market, Can4Med can now quickly satisfy doctor and patient demand throughout the country.
“With an ageing population of over 40 million and openness to natural medicine, Poland is the perfect growth opportunity for medical cannabis in Europe.”
Can4Med supports the work of pharmacists and doctors for the benefit of patients, focusing on ensuring supplies of high-quality certified products and innovation.
The company will offer a variety of products, tailored to the needs of its contractors and patients.
Poland’s doctors have the freedom to use their own judgement in prescribing cannabis medicine, greatly expanding its usage to treat a wide range of medical problems including mental health conditions such as anxiety and depression.
It is estimated that over 300,000 patients will be eligible to obtain cannabinoid medicine in various forms.
All Can4Med products are approved for sale in Poland and manufactured under GMP conditions and are subject to constant quality control.
[activecampaign form=31]
- Hemspan progresses with plans for hemp houses
- Panaxia and Neuraxpharm to bring medical cannabis products to Poland
- Cannabis testing sector expect to blossom as demand ratchets up
- How COVID has and will continue to change the cannabis market
- German cannabis legalisation could increase investment from America